Literature DB >> 25359993

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.

Andre Weilemann1, Michael Grau2, Tabea Erdmann3, Olaf Merkel4, Ulduz Sobhiafshar5, Ioannis Anagnostopoulos6, Michael Hummel6, Antje Siegert7, Claudia Hayford8, Hannelore Madle3, Brigitte Wollert-Wulf9, Iduna Fichtner7, Bernd Dörken9, Stephan Dirnhofer10, Stephan Mathas9, Martin Janz9, N C Tolga Emre5, Andreas Rosenwald11, German Ott12, Peter Lenz2, Alexandar Tzankov10, Georg Lenz3.   

Abstract

Anaplastic large cell lymphoma (ALCL) is a distinct entity of T-cell lymphoma that can be divided into 2 subtypes based on the presence of translocations involving the ALK gene (ALK(+) and ALK(-) ALCL). The interferon regulatory factor 4 (IRF4) is known to be highly expressed in both ALK(+) and ALK(-) ALCLs. However, the role of IRF4 in the pathogenesis of these lymphomas remains unclear. Here we show that ALCLs of both subtypes are addicted to IRF4 signaling, as knockdown of IRF4 by RNA interference was toxic to ALCL cell lines in vitro and in ALCL xenograft mouse models in vivo. Gene expression profiling after IRF4 knockdown demonstrated a significant downregulation of a variety of known MYC target genes. Furthermore, our analyses revealed that MYC is a primary target of IRF4, identifying a novel regulatory mechanism of MYC expression and its target gene network in ALCL. MYC, itself, is essential for ALCL survival, as both knockdown of MYC and pharmacologic inhibition of MYC signaling were toxic to ALCL cell lines. Collectively, our results demonstrate that ALCLs are dependent on IRF4 and MYC signaling and that MYC may represent a promising target for future therapies.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359993     DOI: 10.1182/blood-2014-08-594507

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Authors:  V Atsaves; N Tsesmetzis; D Chioureas; L Kis; V Leventaki; E Drakos; T Panaretakis; D Grander; L J Medeiros; K H Young; G Z Rassidakis
Journal:  Leukemia       Date:  2017-03-27       Impact factor: 11.528

3.  A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.

Authors:  Jing-Ping Zhang; Zhihui Song; Hong-Bo Wang; Lang Lang; Yuan-Zhong Yang; Wenming Xiao; Daniel E Webster; Wei Wei; Stefan K Barta; Marshall E Kadin; Louis M Staudt; Masao Nakagawa; Yibin Yang
Journal:  Blood       Date:  2019-05-31       Impact factor: 22.113

Review 4.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

5.  Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Authors:  Rebecca A Luchtel; Michael T Zimmermann; Guangzhen Hu; Surendra Dasari; Manli Jiang; Naoki Oishi; Hailey K Jacobs; Yu Zeng; Tanya Hundal; Karen L Rech; Rhett P Ketterling; Jeong-Heon Lee; Bruce W Eckloff; Huihuang Yan; Krutika S Gaonkar; Shulan Tian; Zhenqing Ye; Marshall E Kadin; Jagmohan Sidhu; Liuyan Jiang; Jesse Voss; Brian K Link; Sergei I Syrbu; Fabio Facchetti; N Nora Bennani; Susan L Slager; Tamas Ordog; Jean-Pierre Kocher; James R Cerhan; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2019-05-17       Impact factor: 22.113

6.  IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Authors:  Nina Prokoph; Nicola A Probst; Liam C Lee; Jack M Monahan; Jamie D Matthews; Huan-Chang Liang; Klaas Bahnsen; Ivonne A Montes-Mojarro; Elif Karaca-Atabay; Geeta G Sharma; Vikas Malik; Hugo Larose; Sorcha D Forde; Stephen P Ducray; Cosimo Lobello; Qi Wang; Shi-Lu Luan; Šárka Pospíšilová; Carlo Gambacorti-Passerini; G A Amos Burke; Shahid Pervez; Andishe Attarbaschi; Andrea Janíková; Hélène Pacquement; Judith Landman-Parker; Anne Lambilliotte; Gudrun Schleiermacher; Wolfram Klapper; Ralf Jauch; Wilhelm Woessmann; Gilles Vassal; Lukas Kenner; Olaf Merkel; Luca Mologni; Roberto Chiarle; Laurence Brugières; Birgit Geoerger; Isaia Barbieri; Suzanne D Turner
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 7.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

8.  An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.

Authors:  A Lollies; S Hartmann; M Schneider; T Bracht; A L Weiß; J Arnolds; L Klein-Hitpass; B Sitek; M-L Hansmann; R Küppers; M A Weniger
Journal:  Leukemia       Date:  2017-06-29       Impact factor: 11.528

9.  Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Authors:  M Pfeifer; B Zheng; T Erdmann; H Koeppen; R McCord; M Grau; A Staiger; A Chai; T Sandmann; H Madle; B Dörken; Y-W Chu; A I Chen; D Lebovic; G A Salles; M S Czuczman; M C Palanca-Wessels; O W Press; R Advani; F Morschhauser; B D Cheson; P Lenz; G Ott; A G Polson; K E Mundt; G Lenz
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

Review 10.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.